Business
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
BOSTON, June 26, 2025--PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset & $175M Private Placement
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/020f660e4a30d36845c11119582a1352"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/geokEAv9XQajktA9xpjVuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/020f660e4a30d36845c11119582a1352","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.wzBzRXnYnALgupjVM8nNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/020f660e4a30d36845c11119582a1352","width":1200,"height":385}},"lazy":false},{"type":"text","content":"BOSTON, June 26, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity, Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.","length":1155,"tagName":"p"},{"type":"text","content":"Vor Bio separately announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $175 million, before deducting expenses.","length":262,"tagName":"p"},{"type":"text","content":"Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio...